DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
MENLO PARK, Calif., Feb. 02, 2017 -- Pacific Biosciences of California, Inc. (NASDAQ:PACB) today announced financial results for its fourth quarter ended December 31, 2016.
Revenue for the fourth quarter of 2016 totaled $25.7 million, compared to $36.3 million for the fourth quarter of 2015. Product and service revenue for the fourth quarter of 2016 increased 92.2% to $24.4 million, compared to $12.7 million for the fourth quarter of 2015. Contractual revenue for the fourth quarter of 2016 was $1.3 million, reflecting the remaining $1.3 million of amortization of the upfront payment recognizable upon the termination of the Company’s development, commercialization and license agreement with F. Hoffman-La Roche Ltd in December 2016. Contractual revenue for the fourth quarter of 2015 was $23.6 million, reflecting $20.0 million of milestone revenue from Roche and $3.6 million of quarterly amortization of the upfront Roche payment.
Gross profit for the fourth quarter of 2016 was $11.4 million, resulting in a gross margin of 44.2%, compared to gross profit of $26.5 million and a gross margin of 72.9% for the fourth quarter of 2015. The gross profit and margin for the fourth quarter of 2015 was primarily driven by the $20.0 million revenue milestone from Roche, which had a 100% gross margin. Excluding this milestone revenue, gross profit and gross margin for the fourth quarter of 2016 increased significantly over the same period in 2015 primarily as a result of the higher margin sales of the Company’s SequelTM System which was launched in the fourth quarter of 2015.
Operating expenses totaled $29.3 million for the fourth quarter of 2016, compared to $27.5 million for the fourth quarter of 2015. Operating expenses for the fourth quarters of 2016 and 2015 included non-cash stock-based compensation of $4.3 million and $3.6 million, respectively.
The net loss for the fourth quarter of 2016 was $19.0 million, compared to a net loss of $1.4 million for the fourth quarter of 2015.
Cash, cash equivalents and investments, excluding restricted cash, at December 31, 2016 totaled $72.0 million, compared to $82.3 million at December 31, 2015.
Quarterly Conference Call Information
Management will host a quarterly conference call to discuss its fourth quarter 2016 results today at 4:30 p.m. Eastern Time. Investors may listen to the call by dialing 1.888.366.7247, or if outside the U.S., by dialing +1.707.287.9330,using an Audience Passcode of 6231-3559. The call will be webcast live and will be available for replay at Pacific Biosciences’ website at http://investor.pacificbiosciences.com/.
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) Technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and is the only DNA sequencing technology that provides the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the timeline for Pacific Biosciences’ potential development of products, future uses, quality or performance of, or benefits of using, products or technologies and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.
| Pacific Biosciences of California, Inc. | ||||||||||||||||
| Unaudited Condensed Consolidated Statement of Operations | ||||||||||||||||
| (amounts in thousands, except per share amounts) | ||||||||||||||||
| Three-month Periods Ended | Twelve-month Periods Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2016 | 2015 | 2016 | 2015 | |||||||||||||
| Revenue: | ||||||||||||||||
| Product revenue | $ | 20,593 | $ | 9,799 | $ | 64,609 | $ | 37,502 | ||||||||
| Service and other revenue | 3,783 | 2,886 | 13,971 | 10,896 | ||||||||||||
| Contractual revenue | 1,346 | 23,596 | 12,134 | 44,384 | ||||||||||||
| Total revenue | 25,722 | 36,281 | 90,714 | 92,782 | ||||||||||||
| Cost of Revenue: | ||||||||||||||||
| Cost of product revenue | 11,244 | 7,415 | 34,512 | 30,704 | ||||||||||||
| Cost of service and other revenue | 3,104 | 2,400 | 12,042 | 8,628 | ||||||||||||
| Total cost of revenue | 14,348 | 9,815 | 46,554 | 39,332 | ||||||||||||
| Gross profit | 11,374 | 26,466 | 44,160 | 53,450 | ||||||||||||
| Operating Expense: | ||||||||||||||||
| Research and development | 16,255 | 14,752 | 67,617 | 60,440 | ||||||||||||
| Sales, general and administrative | 12,993 | 12,776 | 47,787 | 45,187 | ||||||||||||
| Gain on lease amendments | — | — | — | (23,043 | ) | |||||||||||
| Total operating expense | 29,248 | 27,528 | 115,404 | 82,584 | ||||||||||||
| Operating loss | (17,874 | ) | (1,062 | ) | (71,244 | ) | (29,134 | ) | ||||||||
| Interest expense | (839 | ) | (773 | ) | (3,234 | ) | (2,926 | ) | ||||||||
| Other income (expense), net | (317 | ) | 426 | 103 | 364 | |||||||||||
| Net loss | $ | (19,030 | ) | $ | (1,409 | ) | $ | (74,375 | ) | $ | (31,696 | ) | ||||
| Basic and diluted net loss per share | $ | (0.21 | ) | $ | (0.02 | ) | $ | (0.83 | ) | $ | (0.42 | ) | ||||
| Shares used in computing basic and diluted net loss per share | 92,660 | 78,327 | 89,148 | 75,614 | ||||||||||||
| Pacific Biosciences of California, Inc. | |||||
| Unaudited Condensed Consolidated Balance Sheets | |||||
| (amounts in thousands) | |||||
| December 31, | December 31, | ||||
| 2016 | 2015 | ||||
| Assets | |||||
| Cash and investments | $ | 71,978 | $ | 82,270 | |
| Accounts receivable | 11,421 | 5,245 | |||
| Inventory | 15,634 | 10,955 | |||
| Prepaid and other current assets | 9,978 | 12,071 | |||
| Property and equipment | 14,560 | 8,548 | |||
| Long-term restricted cash | 4,500 | 4,500 | |||
| Other long-term Assets | 9,813 | 7,518 | |||
| Total Assets | $ | 137,884 | $ | 131,107 | |
| Liabilities and Stockholders' Equity | |||||
| Accounts payable | $ | 8,359 | $ | 4,749 | |
| Accrued expenses | 16,604 | 15,551 | |||
| Deferred service revenue | 8,427 | 7,958 | |||
| Deferred contractual revenue | — | 12,134 | |||
| Other liabilities | 3,364 | 1,627 | |||
| Financing derivative | 356 | 600 | |||
| Notes payable | 16,106 | 14,948 | |||
| Stockholders' equity | 84,668 | 73,540 | |||
| Total Liabilities and Stockholders' Equity | $ | 137,884 | $ | 131,107 | |
Contact: Trevin Rard 650.521.8450 [email protected]
